心臓マーカー検査市場:製品(試薬、機器)、成分(トロポニンI&T、CK-MB、ミオグロビン、BNP、hs-CRP)、疾患(心筋梗塞、うっ血性心不全、動脈硬化)、エンドユーザー(ラボ、POC、アカデミア)-2027年までの世界市場予測Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027 心臓マーカー検査の世界市場は、2022年の50億米ドルから2027年には77億米ドルに達し、予測期間中に8.7%のCAGRで推移すると予測されます。心臓マーカー検査市場の成長は、心血管疾患の著しい増加、高齢者人口の急... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー心臓マーカー検査の世界市場は、2022年の50億米ドルから2027年には77億米ドルに達し、予測期間中に8.7%のCAGRで推移すると予測されます。心臓マーカー検査市場の成長は、心血管疾患の著しい増加、高齢者人口の急増、心臓疾患の診断に有効な新規心臓バイオマーカーを発見するための官民組織による研究・資金提供の取り組みが増加していることが主な要因となっています。米国心臓協会(AHA)によると、米国におけるCVDの有病率は2010年の36.9%から2030年には全人口の40.5%に達すると予測されています。しかし、サンプルの採取や保管に伴う技術的な問題、規制や償還制度に関わる問題などが、市場の成長をある程度抑制する要因として予想されています。 "2021年の心臓マーカー検査市場、バイオマーカータイプ別ではトロポニンIとTの推定値が最大シェアを占める " バイオマーカータイプに基づき、心臓マーカー検査市場は、トロポニンIおよびT、クレアチンキナーゼ-MB(CK-MB)、ナトリウム利尿ペプチド(BNPおよびNt-proBNP)、ミオグロビン、高感度CRP(hs-CRP)、その他の心臓マーカーに区分されます。2021年の心臓マーカー検査市場では、トロポニンIおよびTのセグメントが51.1%の最大シェアを占めています。 高い感度と特異度、長い上昇時間(4~8時間で上昇、10~24時間でピーク、10日間で低下)、迅速な予後予測などの要因が、このセグメントの成長を促進しています。また、検査技師は他のバイオマーカーと比較して、これらのマーカーの使用に精通しています。 "2021年の心臓マーカー検査市場において、エンドユーザー別では検査施設分野が最大のシェアを占めている". エンドユーザーに基づき、心臓マーカー検査市場は、ラボラトリー検査施設、学術機関、ポイントオブケア検査施設に区分される。2021年には、ラボラトリー検査施設セグメントが世界の心臓マーカー検査市場で61.4%の最大シェアを占めた。高い検査スループット、POC検査と比較した優れた感度&診断精度、POCT検査よりもラボ検査への高い嗜好性などの要因が、このセグメントの成長を促進している。 "アジア太平洋地域は予測期間中に最も高いCAGRで成長する" 心臓マーカー検査市場は、北米、欧州、アジア太平洋、中南米、中東・アフリカの5つの主要地域に区分されます。アジア太平洋地域は、予測期間中に心臓マーカー検査で最も急速に成長する市場と推定されます。アジア太平洋地域の市場は、医療インフラ改善のためのアジア太平洋地域の新興国の政府機関による投資の増加、独立した臨床検査機関の数の増加、大規模な患者集団の存在、およびアジア太平洋地域における心臓検査製品のリーチを拡大するためにプレーヤーが採用する戦略によって牽引されています。 供給側の一次取材の内訳。 - 企業タイプ別ティア1:48%、ティア2:36%、ティア3:16%。 - 役職別Cレベル:10%、Dレベル:14%、その他。76% - 地域別北米:40%、欧州:32%、APAC:20%、中南米:5%、中東・アフリカ:3 心臓マーカー検査市場に参入している主な企業は、F.Hoffmann-La Roche AG(スイス)、Abbott Laboratories(米国)、Danaher Corporation(米国)、Siemens Healthineers AG(ドイツ)、PerkinElmer,Inc.(米国)、bioMérieux SA(フランス)、Becton, Dickinson and Company(米国)、Bio-Rad Laboratories, Inc(米国)、Thermo Fisher Scientific Inc(米国)、DiaSorin(イタリア)、東ソー株式会社(日本)、LSI Medience Corporation(日本)、Quidel Corporation(米国)、Randox Laboratories(英国)、Guangzhou Wondfo Biotech Co,Ltd.(中国)、ボディテックメッド社(韓国)、チューリップ・ダイアグノスティックス(P)社(インド)、BTNX社(カナダ)、レスポンスバイオメディカル社(カナダ)、Alfa Scientific Designs, Inc(米国)、CTK Biotech, Inc(米国)、Creative Diagnostics(米国)、LifeSign LLC.(米国)、CardioGenics Holdings Inc(カナダ)、Atlas Medical GmbH(ドイツ)。 調査対象 当レポートでは、心臓マーカー検査市場を製品、バイオマーカータイプ、疾患、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因(促進要因、阻害要因、機会、課題など)を調査し、市場リーダー向けの競争環境の詳細も提供しています。さらに、ミクロ市場を個々の成長動向に関して分析し、主要5地域(およびこれらの地域のそれぞれの国)に関して、市場セグメントの収益を予測しています。 レポート購入の主なメリット 本レポートでは、様々なレベルの分析-産業動向、トップ企業の市場シェア、企業プロファイル-に焦点を当て、これらを合わせて基本的な見解を形成し、競争環境、心臓マーカー検査市場の新興セグメント、高成長地域とそのドライバー、抑制、機会、課題などを分析します。本レポートは、既存企業だけでなく、新規参入企業/中小企業にとっても、市場の脈拍を測り、より大きな市場シェアを獲得するのに役立つことでしょう。 目次1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 STUDY SCOPE 29 1.3.1 MARKETS COVERED 29 1.3.2 GEOGRAPHIC SCOPE 29 1.3.3 INCLUSIONS & EXCLUSIONS 30 1.3.4 YEARS CONSIDERED 30 1.4 CURRENCY CONSIDERED 30 1.5 LIMITATIONS 30 1.6 MARKET STAKEHOLDERS 31 1.7 SUMMARY OF CHANGES 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 FIGURE 1 RESEARCH DESIGN 32 2.1.1 SECONDARY RESEARCH 33 2.1.2 PRIMARY RESEARCH 34 2.1.2.1 Key data from primary sources 34 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35 FIGURE 3 CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES 35 2.2 MARKET SIZE ESTIMATION 35 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36 2.2.2 MARKET ESTIMATION BASED ON END USERS 37 FIGURE 5 CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION 37 2.2.3 PRIMARY RESEARCH VALIDATION 37 2.3 DATA TRIANGULATION 38 FIGURE 6 DATA TRIANGULATION METHODOLOGY 38 2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 39 2.4.1 RESEARCH ASSUMPTIONS 39 2.4.2 RESEARCH LIMITATIONS 39 3 EXECUTIVE SUMMARY 40 FIGURE 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) 40 FIGURE 8 CARDIAC MARKER TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 41 FIGURE 9 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET 42 4 PREMIUM INSIGHTS 43 4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 43 FIGURE 10 RISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET 43 4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027 43 FIGURE 11 REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 43 4.3 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION 44 FIGURE 12 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 44 4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT 44 FIGURE 13 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 44 5 MARKET OVERVIEW 45 5.1 INTRODUCTION 45 5.2 MARKET DYNAMICS 45 FIGURE 14 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45 5.2.1 DRIVERS 46 5.2.1.1 Rising incidence of cardiovascular diseases 46 5.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 46 5.2.1.3 Growing research & funding initiatives from public & private organizations 47 5.2.1.4 Rising clinical studies for identification of novel cardiac biomarkers 47 5.2.2 RESTRAINTS 47 5.2.2.1 Technical issues related to sample collection & storage 47 5.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 48 5.2.3 OPPORTUNITIES 48 5.2.3.1 Point-of-care testing with cardiac biomarkers 48 5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 49 5.2.3.3 Emerging markets offer high-growth opportunities 49 5.2.4 CHALLENGES 50 5.2.4.1 Challenges associated with biomarker assay validation 50 5.3 REGULATORY SCENARIO 50 TABLE 1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 50 5.3.1 KEY REGULATORY GUIDELINES 51 5.3.1.1 US 51 TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 51 FIGURE 15 US: REGULATORY PROCESS FOR IVD DEVICES 52 5.3.1.2 Canada 53 FIGURE 16 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 53 5.3.1.3 Europe 53 TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES 53 FIGURE 17 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 54 5.3.1.4 Japan 55 FIGURE 18 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 55 TABLE 4 JAPAN: CLASSIFICATION OF IVD REAGENTS CLASSIFICATION OF IVD REAGENTS IN JAPAN 55 TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56 5.3.1.5 China 56 TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56 5.3.1.6 India 56 FIGURE 19 INDIA: REGULATORY PROCESS FOR IVD DEVICES 57 5.3.1.7 Russia 57 TABLE 7 RUSSIA: CLASSIFICATION OF IVD DEVICES 57 5.3.1.8 Mexico 58 FIGURE 20 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 58 TABLE 8 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 58 5.3.1.9 Brazil 59 FIGURE 21 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 59 5.3.1.10 South Korea 59 TABLE 9 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 59 5.4 REIMBURSEMENT SCENARIO 60 TABLE 10 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 60 5.5 VALUE CHAIN ANALYSIS 61 FIGURE 22 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 61 5.6 SUPPLY CHAIN ANALYSIS 62 FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63 5.7 ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS) 63 5.8 PRICING ANALYSIS 64 5.8.1 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS 64 TABLE 11 CARDIAC BIOMARKER TROPONIN I AND T TEST KITS 64 TABLE 12 CARDIAC BIOMARKER CK-MB TEST KITS 64 TABLE 13 CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS 64 TABLE 14 CARDIAC BIOMARKER MYOGLOBIN TEST KITS 64 TABLE 15 CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS 65 TABLE 16 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD) 65 5.9 PORTER’S FIVE FORCES ANALYSIS 65 TABLE 17 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 65 5.9.1 BARGAINING POWER OF BUYERS 66 5.9.2 BARGAINING POWER OF SUPPLIERS 66 5.9.3 THREAT OF NEW ENTRANTS 66 5.9.4 THREAT OF SUBSTITUTES 66 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66 5.10 PATENT ANALYSIS 67 FIGURE 24 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67 FIGURE 25 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67 5.11 KEY CONFERENCES & EVENTS (2022–2024) 68 TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 68 5.12 CASE STUDY 69 5.12.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 69 TABLE 19 CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS 69 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 70 5.14.1 KEY STAKEHOLDERS 70 FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS 70 TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 70 5.15 KEY BUYING CRITERIA BY END USERS 71 TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS 71 6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 72 6.1 INTRODUCTION 73 TABLE 22 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 73 6.2 REAGENTS & KITS 73 6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND 73 TABLE 23 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020–2027 (USD MILLION) 74 TABLE 24 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 74 6.3 INSTRUMENTS 75 TABLE 25 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION) 75 TABLE 26 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75 TABLE 27 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 76 6.3.1 CHEMILUMINESCENCE 76 6.3.1.1 Most preferred method for quantification of cardiac biomarkers to drive segment growth 76 TABLE 28 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020–2027 (USD MILLION) 77 TABLE 29 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 77 6.3.2 IMMUNOFLUORESCENCE 78 6.3.2.1 Demand for stable and safer reagents to support market growth 78 TABLE 30 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020–2027 (USD MILLION) 78 TABLE 31 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 79 6.3.3 ELISA 79 6.3.3.1 Long shelf life and ease of use to propel segment growth 79 TABLE 32 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 79 TABLE 33 CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 80 6.3.4 IMMUNOCHROMATOGRAPHY 80 6.3.4.1 Increasing use in point-of-care settings to drive adoption of this technique 80 TABLE 34 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 81 TABLE 35 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 81 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 82 7.1 INTRODUCTION 83 TABLE 36 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 83 7.2 TROPONIN I AND T 83 7.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 83 TABLE 37 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS 84 TABLE 38 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020–2027 (USD MILLION) 84 TABLE 39 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020–2027 (USD MILLION) 85 TABLE 40 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020–2027 (USD MILLION) 85 7.3 CREATINE KINASE-MB (CK-MB) 85 7.3.1 DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET 85 TABLE 41 CHARACTERISTICS OF CK-MB CARDIAC MARKER 86 TABLE 42 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020–2027 (USD MILLION) 86 TABLE 43 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020–2027 (USD MILLION) 87 TABLE 44 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020–2027 (USD MILLION) 87 7.4 NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) 87 7.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 87 TABLE 45 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020–2027 (USD MILLION) 88 TABLE 46 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020–2027 (USD MILLION) 88 TABLE 47 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020–2027 (USD MILLION) 89 7.5 MYOGLOBIN 89 7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET 89 TABLE 48 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS 89 TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020–2027 (USD MILLION) 90 TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020–2027 (USD MILLION) 90 TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020–2027 (USD MILLION) 91 7.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) 91 7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH 91 TABLE 52 CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS 91 TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY REGION, 2020–2027 (USD MILLION) 92 TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY DISEASE, 2020–2027 (USD MILLION) 92 TABLE 55 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY END USER, 2020–2027 (USD MILLION) 93 7.7 OTHER CARDIAC BIOMARKERS 93 TABLE 56 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 94 TABLE 57 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020–2027 (USD MILLION) 94 TABLE 58 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020–2027 (USD MILLION) 95 8 CARDIAC MARKER TESTING MARKET, BY DISEASE 96 8.1 INTRODUCTION 97 TABLE 59 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020–2027 (USD MILLION) 97 8.2 MYOCARDIAL INFARCTION 97 8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET 97 TABLE 60 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020–2027 (USD MILLION) 98 8.3 CONGESTIVE HEART FAILURE 98 8.3.1 INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH 98 TABLE 61 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020–2027 (USD MILLION) 99 8.4 ACUTE CORONARY SYNDROME 99 8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 99 TABLE 62 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020–2027 (USD MILLION) 100 8.5 ATHEROSCLEROSIS 100 8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS 100 TABLE 63 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020–2027 (USD MILLION) 101 8.6 ISCHEMIA 101 8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS 101 TABLE 64 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION) 101 9 CARDIAC MARKER TESTING MARKET, BY END USER 102 9.1 INTRODUCTION 103 TABLE 65 CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 103 9.2 LABORATORY TESTING FACILITIES 103 TABLE 66 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020–2027 (USD MILLION) 104 TABLE 67 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 104 9.2.1 HOSPITAL LABORATORIES 104 9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market 104 TABLE 68 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105 9.2.2 REFERENCE LABORATORIES 105 9.2.2.1 Affordable and time-efficient services associated with reference laboratories to support market growth 105 TABLE 69 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105 9.2.3 CONTRACT TESTING LABORATORIES 106 9.2.3.1 Ability to perform multiple tests and cover wider matrices to support market growth 106 TABLE 70 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 106 9.3 ACADEMIC INSTITUTES 106 9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 106 TABLE 71 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 107 9.4 POINT-OF-CARE TESTING FACILITIES 107 9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET 107 TABLE 72 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 108 10 CARDIAC MARKER TESTING MARKET, BY REGION 109 10.1 INTRODUCTION 110 TABLE 73 CARDIAC MARKER TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 110 10.2 NORTH AMERICA 110 FIGURE 27 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 111 TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111 TABLE 75 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 112 TABLE 76 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112 TABLE 77 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 113 TABLE 78 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 113 10.2.1 US 113 10.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 113 TABLE 79 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114 10.2.2 CANADA 114 10.2.2.1 Increasing government initiatives supporting cardiac marker testing to boost market growth 114 TABLE 80 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 115 10.3 EUROPE 115 TABLE 81 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115 TABLE 82 EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 116 TABLE 83 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116 TABLE 84 EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 116 TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 117 10.3.1 GERMANY 117 10.3.1.1 Higher healthcare expenditure to drive demand for diagnostic tests 117 TABLE 86 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 117 10.3.2 UK 118 10.3.2.1 Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers 118 TABLE 87 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118 10.3.3 FRANCE 118 10.3.3.1 Rising demand for early CVD diagnosis to drive market 118 TABLE 88 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119 10.3.4 ITALY 119 10.3.4.1 Adoption of advanced diagnostic technologies to drive market 119 TABLE 89 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119 10.3.5 SPAIN 120 10.3.5.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 120 TABLE 90 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 120 10.3.6 REST OF EUROPE (ROE) 120 TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121 10.4 ASIA PACIFIC 121 FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 122 TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 123 TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124 TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124 TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 124 10.4.1 JAPAN 125 10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market 125 TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 125 10.4.2 CHINA 125 10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers 125 TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126 10.4.3 INDIA 126 10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing 126 TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127 10.4.4 SOUTH KOREA 127 10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services 127 TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127 10.4.5 AUSTRALIA 128 10.4.5.1 High healthcare expenditure to support market growth 128 TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128 10.4.6 REST OF ASIA PACIFIC (ROAPAC) 128 TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128 10.5 LATIN AMERICA 129 TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129 TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 130 TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130 TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130 TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 131 10.5.1 BRAZIL 131 10.5.1.1 Rising government support for advancements in healthcare to support market growth 131 TABLE 108 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 131 10.5.2 MEXICO 132 10.5.2.1 Rising demand for technologically advanced products to drive uptake for cardiac markers 132 TABLE 109 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 132 10.5.3 REST OF LATIN AMERICA (ROLATAM) 132 TABLE 110 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133 10.6 MIDDLE EAST & AFRICA 133 10.6.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS 133 TABLE 111 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 133 TABLE 112 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 134 TABLE 113 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 134 TABLE 114 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 134 11 COMPETITIVE LANDSCAPE 135 11.1 OVERVIEW 135 11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 135 FIGURE 29 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022) 136 11.3 REVENUE ANALYSIS 137 FIGURE 30 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018−2021) 137 11.4 CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 137 FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021) 138 TABLE 115 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION 138 11.5 COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021) 139 11.5.1 STARS 139 11.5.2 EMERGING LEADERS 139 11.5.3 PERVASIVE PLAYERS 139 11.5.4 PARTICIPANTS 140 FIGURE 32 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION QUADRANT (2021) 140 11.6 COMPANY EVALUATION QUADRANT (SMES/STARTUPS) 141 11.6.1 PROGRESSIVE COMPANIES 141 11.6.2 RESPONSIVE COMPANIES 141 11.6.3 DYNAMIC COMPANIES 141 11.6.4 STARTING BLOCKS 141 FIGURE 33 CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) 142 11.7 COMPETITIVE BENCHMARKING 143 TABLE 116 OVERALL FOOTPRINT ANALYSIS 143 TABLE 117 PRODUCT FOOTPRINT ANALYSIS 144 TABLE 118 REGIONAL FOOTPRINT ANALYSIS 145 11.8 COMPETITIVE SCENARIO (2019–2022) 146 11.8.1 PRODUCT LAUNCHES & APPROVALS 146 11.8.2 DEALS 147 11.8.3 OTHER DEVELOPMENTS 147 12 COMPANY PROFILES 148 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1 KEY PLAYERS 148 12.1.1 F. HOFFMANN-LA ROCHE AG 148 TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 148 FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 149 12.1.2 ABBOTT LABORATORIES 152 TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW 152 FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 153 12.1.3 SIEMENS HEALTHINEERS AG 156 TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 156 FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 157 12.1.4 DANAHER CORPORATION 160 TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW 160 FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 161 12.1.5 BIOMÉRIEUX SA 163 TABLE 123 BIOMÉRIEUX SA: BUSINESS OVERVIEW 163 FIGURE 38 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 164 12.1.6 BECTON, DICKINSON AND COMPANY (BD) 165 TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 165 FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 166 12.1.7 BIO-RAD LABORATORIES, INC. 168 TABLE 125 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW 168 FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 169 12.1.8 THERMO FISHER SCIENTIFIC INC. 171 TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 171 FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 172 12.1.9 DIASORIN 174 TABLE 127 DIASORIN: BUSINESS OVERVIEW 174 FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021) 175 12.1.10 PERKINELMER, INC. 177 TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW 177 FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021) 178 12.1.11 TOSOH CORPORATION 180 TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW 180 FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022) 181 12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 184 TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW 184 FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 184 12.1.13 QUIDEL CORPORATION 186 TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW 186 FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 186 12.1.14 RANDOX LABORATORIES 188 TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW 188 12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 190 TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 190 12.1.16 BODITECH MED INC. 192 TABLE 134 BODITECH MED INC: BUSINESS OVERVIEW 192 12.1.17 TULIP (P) DIAGNOSTICS LTD 194 TABLE 135 TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW 194 12.1.18 BTNX INC. 195 TABLE 136 BTNX INC.: BUSINESS OVERVIEW 195 12.1.19 RESPONSE BIOMEDICAL 196 TABLE 137 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 196 12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 198 TABLE 138 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW 198 12.2 OTHER PLAYERS 199 12.2.1 CTK BIOTECH, INC. 199 12.2.2 CREATIVE DIAGNOSTICS 199 12.2.3 LIFESIGN LLC. 200 12.2.4 CARDIOGENICS HOLDINGS INC 200 12.2.5 ATLAS MEDICAL GMBH 201 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 202 13.1 DISCUSSION GUIDE 202 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206 13.3 CUSTOMIZATION OPTIONS 208 13.4 RELATED REPORTS 209 13.5 AUTHOR DETAILS 210
SummaryThe global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period. The growth in the cardiac marker testing market is majorly driven by the significant rising cases of cardiovascular diseases, rapid growth in older population, and increasing research & funding initiatives from public/private organizations to discover novel cardiac biomarkers with improved efficacy for diagnosing heart conditions. According to the American Heart Association (AHA), the prevalence of CVD in the US is projected to reach 40.5% of the total population by 2030, from 36.9% in 2010. Table of Contents1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 STUDY SCOPE 29 1.3.1 MARKETS COVERED 29 1.3.2 GEOGRAPHIC SCOPE 29 1.3.3 INCLUSIONS & EXCLUSIONS 30 1.3.4 YEARS CONSIDERED 30 1.4 CURRENCY CONSIDERED 30 1.5 LIMITATIONS 30 1.6 MARKET STAKEHOLDERS 31 1.7 SUMMARY OF CHANGES 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 FIGURE 1 RESEARCH DESIGN 32 2.1.1 SECONDARY RESEARCH 33 2.1.2 PRIMARY RESEARCH 34 2.1.2.1 Key data from primary sources 34 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35 FIGURE 3 CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES 35 2.2 MARKET SIZE ESTIMATION 35 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36 2.2.2 MARKET ESTIMATION BASED ON END USERS 37 FIGURE 5 CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION 37 2.2.3 PRIMARY RESEARCH VALIDATION 37 2.3 DATA TRIANGULATION 38 FIGURE 6 DATA TRIANGULATION METHODOLOGY 38 2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 39 2.4.1 RESEARCH ASSUMPTIONS 39 2.4.2 RESEARCH LIMITATIONS 39 3 EXECUTIVE SUMMARY 40 FIGURE 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) 40 FIGURE 8 CARDIAC MARKER TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 41 FIGURE 9 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET 42 4 PREMIUM INSIGHTS 43 4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 43 FIGURE 10 RISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET 43 4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027 43 FIGURE 11 REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 43 4.3 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION 44 FIGURE 12 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 44 4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT 44 FIGURE 13 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 44 5 MARKET OVERVIEW 45 5.1 INTRODUCTION 45 5.2 MARKET DYNAMICS 45 FIGURE 14 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45 5.2.1 DRIVERS 46 5.2.1.1 Rising incidence of cardiovascular diseases 46 5.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 46 5.2.1.3 Growing research & funding initiatives from public & private organizations 47 5.2.1.4 Rising clinical studies for identification of novel cardiac biomarkers 47 5.2.2 RESTRAINTS 47 5.2.2.1 Technical issues related to sample collection & storage 47 5.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 48 5.2.3 OPPORTUNITIES 48 5.2.3.1 Point-of-care testing with cardiac biomarkers 48 5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 49 5.2.3.3 Emerging markets offer high-growth opportunities 49 5.2.4 CHALLENGES 50 5.2.4.1 Challenges associated with biomarker assay validation 50 5.3 REGULATORY SCENARIO 50 TABLE 1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 50 5.3.1 KEY REGULATORY GUIDELINES 51 5.3.1.1 US 51 TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 51 FIGURE 15 US: REGULATORY PROCESS FOR IVD DEVICES 52 5.3.1.2 Canada 53 FIGURE 16 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 53 5.3.1.3 Europe 53 TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES 53 FIGURE 17 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 54 5.3.1.4 Japan 55 FIGURE 18 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 55 TABLE 4 JAPAN: CLASSIFICATION OF IVD REAGENTS CLASSIFICATION OF IVD REAGENTS IN JAPAN 55 TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56 5.3.1.5 China 56 TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56 5.3.1.6 India 56 FIGURE 19 INDIA: REGULATORY PROCESS FOR IVD DEVICES 57 5.3.1.7 Russia 57 TABLE 7 RUSSIA: CLASSIFICATION OF IVD DEVICES 57 5.3.1.8 Mexico 58 FIGURE 20 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 58 TABLE 8 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 58 5.3.1.9 Brazil 59 FIGURE 21 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 59 5.3.1.10 South Korea 59 TABLE 9 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 59 5.4 REIMBURSEMENT SCENARIO 60 TABLE 10 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 60 5.5 VALUE CHAIN ANALYSIS 61 FIGURE 22 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS 61 5.6 SUPPLY CHAIN ANALYSIS 62 FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 63 5.7 ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS) 63 5.8 PRICING ANALYSIS 64 5.8.1 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS 64 TABLE 11 CARDIAC BIOMARKER TROPONIN I AND T TEST KITS 64 TABLE 12 CARDIAC BIOMARKER CK-MB TEST KITS 64 TABLE 13 CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS 64 TABLE 14 CARDIAC BIOMARKER MYOGLOBIN TEST KITS 64 TABLE 15 CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS 65 TABLE 16 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD) 65 5.9 PORTER’S FIVE FORCES ANALYSIS 65 TABLE 17 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 65 5.9.1 BARGAINING POWER OF BUYERS 66 5.9.2 BARGAINING POWER OF SUPPLIERS 66 5.9.3 THREAT OF NEW ENTRANTS 66 5.9.4 THREAT OF SUBSTITUTES 66 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66 5.10 PATENT ANALYSIS 67 FIGURE 24 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67 FIGURE 25 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022) 67 5.11 KEY CONFERENCES & EVENTS (2022–2024) 68 TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 68 5.12 CASE STUDY 69 5.12.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 69 TABLE 19 CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS 69 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 70 5.14.1 KEY STAKEHOLDERS 70 FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS 70 TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 70 5.15 KEY BUYING CRITERIA BY END USERS 71 TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS 71 6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 72 6.1 INTRODUCTION 73 TABLE 22 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 73 6.2 REAGENTS & KITS 73 6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND 73 TABLE 23 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020–2027 (USD MILLION) 74 TABLE 24 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 74 6.3 INSTRUMENTS 75 TABLE 25 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION) 75 TABLE 26 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75 TABLE 27 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 76 6.3.1 CHEMILUMINESCENCE 76 6.3.1.1 Most preferred method for quantification of cardiac biomarkers to drive segment growth 76 TABLE 28 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020–2027 (USD MILLION) 77 TABLE 29 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 77 6.3.2 IMMUNOFLUORESCENCE 78 6.3.2.1 Demand for stable and safer reagents to support market growth 78 TABLE 30 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020–2027 (USD MILLION) 78 TABLE 31 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 79 6.3.3 ELISA 79 6.3.3.1 Long shelf life and ease of use to propel segment growth 79 TABLE 32 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 79 TABLE 33 CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 80 6.3.4 IMMUNOCHROMATOGRAPHY 80 6.3.4.1 Increasing use in point-of-care settings to drive adoption of this technique 80 TABLE 34 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 81 TABLE 35 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 81 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 82 7.1 INTRODUCTION 83 TABLE 36 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 83 7.2 TROPONIN I AND T 83 7.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 83 TABLE 37 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS 84 TABLE 38 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020–2027 (USD MILLION) 84 TABLE 39 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020–2027 (USD MILLION) 85 TABLE 40 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020–2027 (USD MILLION) 85 7.3 CREATINE KINASE-MB (CK-MB) 85 7.3.1 DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET 85 TABLE 41 CHARACTERISTICS OF CK-MB CARDIAC MARKER 86 TABLE 42 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020–2027 (USD MILLION) 86 TABLE 43 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020–2027 (USD MILLION) 87 TABLE 44 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020–2027 (USD MILLION) 87 7.4 NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) 87 7.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 87 TABLE 45 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020–2027 (USD MILLION) 88 TABLE 46 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020–2027 (USD MILLION) 88 TABLE 47 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020–2027 (USD MILLION) 89 7.5 MYOGLOBIN 89 7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET 89 TABLE 48 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS 89 TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020–2027 (USD MILLION) 90 TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020–2027 (USD MILLION) 90 TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020–2027 (USD MILLION) 91 7.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) 91 7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH 91 TABLE 52 CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS 91 TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY REGION, 2020–2027 (USD MILLION) 92 TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY DISEASE, 2020–2027 (USD MILLION) 92 TABLE 55 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY END USER, 2020–2027 (USD MILLION) 93 7.7 OTHER CARDIAC BIOMARKERS 93 TABLE 56 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 94 TABLE 57 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020–2027 (USD MILLION) 94 TABLE 58 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020–2027 (USD MILLION) 95 8 CARDIAC MARKER TESTING MARKET, BY DISEASE 96 8.1 INTRODUCTION 97 TABLE 59 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020–2027 (USD MILLION) 97 8.2 MYOCARDIAL INFARCTION 97 8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET 97 TABLE 60 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020–2027 (USD MILLION) 98 8.3 CONGESTIVE HEART FAILURE 98 8.3.1 INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH 98 TABLE 61 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020–2027 (USD MILLION) 99 8.4 ACUTE CORONARY SYNDROME 99 8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 99 TABLE 62 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020–2027 (USD MILLION) 100 8.5 ATHEROSCLEROSIS 100 8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS 100 TABLE 63 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020–2027 (USD MILLION) 101 8.6 ISCHEMIA 101 8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS 101 TABLE 64 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION) 101 9 CARDIAC MARKER TESTING MARKET, BY END USER 102 9.1 INTRODUCTION 103 TABLE 65 CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 103 9.2 LABORATORY TESTING FACILITIES 103 TABLE 66 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020–2027 (USD MILLION) 104 TABLE 67 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 104 9.2.1 HOSPITAL LABORATORIES 104 9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market 104 TABLE 68 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105 9.2.2 REFERENCE LABORATORIES 105 9.2.2.1 Affordable and time-efficient services associated with reference laboratories to support market growth 105 TABLE 69 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 105 9.2.3 CONTRACT TESTING LABORATORIES 106 9.2.3.1 Ability to perform multiple tests and cover wider matrices to support market growth 106 TABLE 70 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 106 9.3 ACADEMIC INSTITUTES 106 9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 106 TABLE 71 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 107 9.4 POINT-OF-CARE TESTING FACILITIES 107 9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET 107 TABLE 72 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION) 108 10 CARDIAC MARKER TESTING MARKET, BY REGION 109 10.1 INTRODUCTION 110 TABLE 73 CARDIAC MARKER TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 110 10.2 NORTH AMERICA 110 FIGURE 27 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 111 TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111 TABLE 75 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 112 TABLE 76 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112 TABLE 77 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 113 TABLE 78 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 113 10.2.1 US 113 10.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 113 TABLE 79 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114 10.2.2 CANADA 114 10.2.2.1 Increasing government initiatives supporting cardiac marker testing to boost market growth 114 TABLE 80 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 115 10.3 EUROPE 115 TABLE 81 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115 TABLE 82 EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 116 TABLE 83 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116 TABLE 84 EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 116 TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 117 10.3.1 GERMANY 117 10.3.1.1 Higher healthcare expenditure to drive demand for diagnostic tests 117 TABLE 86 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 117 10.3.2 UK 118 10.3.2.1 Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers 118 TABLE 87 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118 10.3.3 FRANCE 118 10.3.3.1 Rising demand for early CVD diagnosis to drive market 118 TABLE 88 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119 10.3.4 ITALY 119 10.3.4.1 Adoption of advanced diagnostic technologies to drive market 119 TABLE 89 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119 10.3.5 SPAIN 120 10.3.5.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 120 TABLE 90 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 120 10.3.6 REST OF EUROPE (ROE) 120 TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121 10.4 ASIA PACIFIC 121 FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 122 TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 123 TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124 TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124 TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 124 10.4.1 JAPAN 125 10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market 125 TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 125 10.4.2 CHINA 125 10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers 125 TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126 10.4.3 INDIA 126 10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing 126 TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127 10.4.4 SOUTH KOREA 127 10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services 127 TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127 10.4.5 AUSTRALIA 128 10.4.5.1 High healthcare expenditure to support market growth 128 TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128 10.4.6 REST OF ASIA PACIFIC (ROAPAC) 128 TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128 10.5 LATIN AMERICA 129 TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129 TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 130 TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130 TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130 TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 131 10.5.1 BRAZIL 131 10.5.1.1 Rising government support for advancements in healthcare to support market growth 131 TABLE 108 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 131 10.5.2 MEXICO 132 10.5.2.1 Rising demand for technologically advanced products to drive uptake for cardiac markers 132 TABLE 109 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 132 10.5.3 REST OF LATIN AMERICA (ROLATAM) 132 TABLE 110 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133 10.6 MIDDLE EAST & AFRICA 133 10.6.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS 133 TABLE 111 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION) 133 TABLE 112 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 134 TABLE 113 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 134 TABLE 114 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 134 11 COMPETITIVE LANDSCAPE 135 11.1 OVERVIEW 135 11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 135 FIGURE 29 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022) 136 11.3 REVENUE ANALYSIS 137 FIGURE 30 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018−2021) 137 11.4 CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 137 FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021) 138 TABLE 115 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION 138 11.5 COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021) 139 11.5.1 STARS 139 11.5.2 EMERGING LEADERS 139 11.5.3 PERVASIVE PLAYERS 139 11.5.4 PARTICIPANTS 140 FIGURE 32 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION QUADRANT (2021) 140 11.6 COMPANY EVALUATION QUADRANT (SMES/STARTUPS) 141 11.6.1 PROGRESSIVE COMPANIES 141 11.6.2 RESPONSIVE COMPANIES 141 11.6.3 DYNAMIC COMPANIES 141 11.6.4 STARTING BLOCKS 141 FIGURE 33 CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) 142 11.7 COMPETITIVE BENCHMARKING 143 TABLE 116 OVERALL FOOTPRINT ANALYSIS 143 TABLE 117 PRODUCT FOOTPRINT ANALYSIS 144 TABLE 118 REGIONAL FOOTPRINT ANALYSIS 145 11.8 COMPETITIVE SCENARIO (2019–2022) 146 11.8.1 PRODUCT LAUNCHES & APPROVALS 146 11.8.2 DEALS 147 11.8.3 OTHER DEVELOPMENTS 147 12 COMPANY PROFILES 148 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1 KEY PLAYERS 148 12.1.1 F. HOFFMANN-LA ROCHE AG 148 TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 148 FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 149 12.1.2 ABBOTT LABORATORIES 152 TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW 152 FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 153 12.1.3 SIEMENS HEALTHINEERS AG 156 TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 156 FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 157 12.1.4 DANAHER CORPORATION 160 TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW 160 FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 161 12.1.5 BIOMÉRIEUX SA 163 TABLE 123 BIOMÉRIEUX SA: BUSINESS OVERVIEW 163 FIGURE 38 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 164 12.1.6 BECTON, DICKINSON AND COMPANY (BD) 165 TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 165 FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 166 12.1.7 BIO-RAD LABORATORIES, INC. 168 TABLE 125 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW 168 FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 169 12.1.8 THERMO FISHER SCIENTIFIC INC. 171 TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 171 FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 172 12.1.9 DIASORIN 174 TABLE 127 DIASORIN: BUSINESS OVERVIEW 174 FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021) 175 12.1.10 PERKINELMER, INC. 177 TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW 177 FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021) 178 12.1.11 TOSOH CORPORATION 180 TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW 180 FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022) 181 12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 184 TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW 184 FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 184 12.1.13 QUIDEL CORPORATION 186 TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW 186 FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 186 12.1.14 RANDOX LABORATORIES 188 TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW 188 12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 190 TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 190 12.1.16 BODITECH MED INC. 192 TABLE 134 BODITECH MED INC: BUSINESS OVERVIEW 192 12.1.17 TULIP (P) DIAGNOSTICS LTD 194 TABLE 135 TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW 194 12.1.18 BTNX INC. 195 TABLE 136 BTNX INC.: BUSINESS OVERVIEW 195 12.1.19 RESPONSE BIOMEDICAL 196 TABLE 137 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 196 12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 198 TABLE 138 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW 198 12.2 OTHER PLAYERS 199 12.2.1 CTK BIOTECH, INC. 199 12.2.2 CREATIVE DIAGNOSTICS 199 12.2.3 LIFESIGN LLC. 200 12.2.4 CARDIOGENICS HOLDINGS INC 200 12.2.5 ATLAS MEDICAL GMBH 201 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 202 13.1 DISCUSSION GUIDE 202 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206 13.3 CUSTOMIZATION OPTIONS 208 13.4 RELATED REPORTS 209 13.5 AUTHOR DETAILS 210
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
MarketsandMarkets社のその他分野での最新刊レポート
本レポートと同じKEY WORD(heart failure)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |